|
|
 |
|
LEF-1, a Central Target in Neutrophil Granulopoiesis with Involvement in Leukemia and NeutropeniaReference Number TO 15-00013
The Challenge
Severe congenital neutropenia (CN) is a disorder of myelopoiesis resulting in recurrent life-threatening infections due to a lack of peripheral blood neutrophils. CN is also considered a pre-leukemic syndrome, because more than 20% of patients with CN progress to acute myelogenous leukaemia (AML). AML is characterized by
uncontrolled proliferation of myeloid progenitors arrested in their maturation process. Several recent studies propose a common regulatory pathway for proper proliferation and differentiation of myeloid progenitors.
The Technology LEF-1 has been found to be a decisive transcription factor in granulopoiesis controlling proliferation, lineage commitment and granulocytic differentiation via regulation of its target genes.
Commercial Opportunity Collaboration to identify therapeutic compounds that can alter LEF-1 activity.
In vitro modulation of LEF-1 level in several cell-culture applications have verified a central role for LEF-1 in granulopoiesis:
Patent situation EP and US patent applications have been filed based on WO2008/034637A1.
Further reading Skokowa and Welte (2007). LEF-1 is a decisive transcription factor in neutrophil granulopoiesis. Ann N Y Acad Sci. Mar 14; Epub ahead of print
Sokowa et al. (2006). LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med. Oct;12(10):1191-7 |
